Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic ...

Each year, some babies experience a lack of oxygen before or during birth, which can lead to brain injury—a medical condition ...

Berlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

The company's application included a submitted dose of 0.04 millimole gadolinium per kilogram of body weight. If approved, gadoquatrane would become the lowest dose macrocyclic gadolinium-based ...

Emphysema subtypes, identified via CT, may be linked to cardiopulmonary subphenotypes that can help to target cardiac care in early COPD.

Adults with a history of childhood trauma show measurable differences in brain structure and function, according to new ...

Repeated TBIs are linked to an increased risk of neurodegenerative diseases like early-onset dementia, which has the highest ...

As the world celebrates the 2025 International Year of Quantum Science and Technology, it’s natural that we should focus on ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on ...

BACKGROUND: Penetrance and risk of ventricular arrhythmias (VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC) are increasingly recognized as being genotype specific. Therefore, ...

Thailand’s leadership in the global cassava industry took centre stage at the Global Cassava Sustainability Forum 2025, held ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases ...